What happens after a BIMO inspection: the 483, the classification, and who is told
The free guide, narrated: the steps after an FDA BIMO inspection of a clinical investigator closes, in their set order, how long each takes, and who is told what.
Transcript
What happens after an FDA Bioresearch Monitoring inspection.
After an inspection of a clinical investigator closes, the steps run in a set order.
The inspector presents any observations on a Form FDA 483, the clinical investigator may respond, the reviewing center classifies the inspection No Action Indicated, Voluntary Action Indicated, or Official Action Indicated, and, for a small share of inspections, FDA acts, with a warning letter or disqualification proceedings.
The sponsor of the trial is not typically told at any of these steps; the one exception is a disqualification.
First, the closing meeting. The observations on the Form FDA 483 are the inspector's; they are not yet FDA's position.
Second, the response. A response is not mandatory, but submitting a response shows FDA that the inspection findings are being taken seriously.
Third, the inspection report. The report, the 483 and any response go to the reviewing center.
Fourth, the classification. The center, not the inspector, classifies the inspection, weeks to months after it closes.
Fifth, FDA writes to the clinical investigator. For most inspections that is the end of the matter: an NAI needs nothing further, and a VAI leaves correction to the clinical investigator.
Sixth, further action, for a few. An OAI often leads eventually to a warning letter. Where FDA believes the violations were repeated or deliberate, it may open disqualification proceedings. That is rare even among OAI inspections.
Seventh, closing the loop. A warning letter stays open until FDA is satisfied with the corrections; FDA may confirm that with a close-out letter, or with another inspection.
How long does it take? Longer than most people expect. The 483 is in hand the day the inspection closes. The classification follows weeks to months later. A warning letter, where there is one, generally comes months after the inspection it is based on. A disqualification proceeding can span two or more years.
In the record, when a warning letter followed an OAI inspection, FDA took a median of about seven and a half months to issue it. Half of them arrived between five and eleven months after the inspection.
At every point in that stretch, the clinical investigator can be running other trials, and being considered for new ones.
Who is told what? FDA sends inspection findings to the clinical investigator, not typically to the sponsor.
The clinical investigator is not required to report an inspection to the sponsor unless a quality agreement between them says so. Disqualification is the exception: FDA notifies the sponsor of any investigation in which that clinical investigator was named.
For a candidate site, an inspection on the record is a read-the-findings situation, not a checkbox. The options are the usual three: ask the site for their responses and corrective action plans, visit the site before signing to perform your own evaluation of its compliance position, or choose a site without this history.
The whole guide is free to read, with no account, at clinicalprecedent.com.